Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last?

Core Viewpoint - Ionis Pharmaceuticals (IONS) experienced a significant stock price increase of 9.1% to $43.59, driven by investor optimism regarding its drug portfolio and pipeline expansion [1][2]. Company Performance - The company is expected to report quarterly earnings of $0.19 per share, reflecting a year-over-year increase of 142.2%. Revenue is anticipated to be $246.31 million, up 9.5% from the same quarter last year [3]. - However, the consensus EPS estimate has been revised 5.5% lower over the past 30 days, indicating a negative trend in earnings estimate revisions, which typically does not lead to price appreciation [4]. Industry Context - Ionis Pharmaceuticals is part of the Zacks Medical - Drugs industry, where another company, Crinetics Pharmaceuticals, Inc. (CRNX), saw a 3.6% increase in its stock price but has returned -11.4% over the past month [5]. - Crinetics Pharmaceuticals has an unchanged consensus EPS estimate of -$1.13, representing a year-over-year change of -20.2% [6].